Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial

IMPORTANCE: Baricitinib, an oral selective Janus kinase 1 and 2 inhibitor, effectively reduced disease severity in moderate to severe atopic dermatitis (AD) in 2 phase 3 monotherapy studies. OBJECTIVE: To assess the efficacy and safety of 4 mg and 2 mg of baricitinib in combination with background t...

Descripción completa

Detalles Bibliográficos
Autores principales: Reich, Kristian, Kabashima, Kenji, Peris, Ketty, Silverberg, Jonathan I., Eichenfield, Lawrence F., Bieber, Thomas, Kaszuba, Aleksandra, Kolodsick, Jill, Yang, Fan E., Gamalo, Margaret, Brinker, Dennis R., DeLozier, Amy M., Janes, Jonathan M., Nunes, Fabio P., Thyssen, Jacob P., Simpson, Eric L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2020
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7527941/
https://www.ncbi.nlm.nih.gov/pubmed/33001140
http://dx.doi.org/10.1001/jamadermatol.2020.3260

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7527941/
https://www.ncbi.nlm.nih.gov/pubmed/33001140
http://dx.doi.org/10.1001/jamadermatol.2020.3260

Ejemplares similares